Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041) - Yamazaki, N; Takenouchi, T; Fujimoto, M (Cancer Chemother Pharmacol, 2017)